BCR inhibitors improving CLL patient outcomes
Combining radiotherapy and the immune system in lymphomas
Is venetoclax appropriate for relapsed CLL patients?
Side effects of novel PI3K inhibitors
Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian